PNC Financial Services Group’s Ocular Therapeutix OCUL Stock Holding History

PNC Financial Services Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.16K	Sell	609 -73	-11%	-$696	﹤0.01%	4253
2025 Q4	$8.28K	Sell	682 -44	-6%	-$534	﹤0.01%	4038
2025 Q3	$8.49K	Buy	726 +215	+42%	+$2.57K	﹤0.01%	4007
2025 Q2	$4.74K	Buy	511 +228	+81%	+$1.78K	﹤0.01%	4156
2025 Q1	$2.07K	Buy	+283	New	+$2.17K	﹤0.01%	4331
2024 Q3	–	Sell	-106	Closed	-$725	–	4873
2024 Q2	$725	Sell	106 -16	-13%	-$99	﹤0.01%	4481
2024 Q1	$1.11K	Buy	122 +111	+1,009%	+$788	﹤0.01%	4345
2023 Q4	$49	Buy	+11	New	+$33	﹤0.01%	4566
2022 Q1	–	Sell	-1,000	Closed	-$7K	–	4652
2021 Q4	$7K	Buy	+1,000	New	+$7.77K	﹤0.01%	3883
2018 Q3	–	Sell	-1,500	Closed	-$10K	–	4203
2018 Q2	$10K	Buy	+1,500	New	+$10.3K	﹤0.01%	3687

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PNC Financial Services Group's OCUL Position: Q1 2026 in Review

PNC Financial Services Group reduced its Ocular Therapeutix (OCUL) stake by 11% in Q1 2026, selling an estimated $696 and leaving 609 shares worth $5.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4253.

PNC Financial Services Group first reported a position in OCUL in Q2 2018 and has held it in 10 quarters since. The position peaked at $10K in Q2 2018. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

PNC Financial Services Group held 609 shares of Ocular Therapeutix worth $5.16K as of Q1 2026.
PNC Financial Services Group sold 73 Ocular Therapeutix shares in Q1 2026, an estimated $696.
Ocular Therapeutix made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4253 holding.
PNC Financial Services Group first reported a position in Ocular Therapeutix in Q2 2018 and has held it in 10 quarters since.
PNC Financial Services Group's Ocular Therapeutix position peaked at $10K in Q2 2018.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.